Aptus Pharma bonus issue approved, capital raised to ₹25 cr

Shareholders clear two corporate actions

Aptus Pharma Ltd said its shareholders have unanimously approved two proposals: a 3:2 bonus issue and a sharp increase in authorised share capital. The approvals came through a postal ballot process, with e-voting conducted via Central Depository Services (India) Ltd (CDSL). The postal ballot concluded on April 25, 2026, and the scrutiniser’s report confirmed the outcome. The company reported 100% support for both resolutions. A total of 5,122,000 votes were cast, all in favour. The board had first approved and recommended these steps at its meeting on March 24, 2026.

What exactly shareholders approved

The first resolution increases Aptus Pharma’s authorised share capital to ₹25.00 crore from ₹7.15 crore. The second is a bonus issue in a 3:2 ratio, meaning shareholders will receive three additional equity shares for every two shares held as on the record date. The face value of each equity share remains ₹10. The company indicated it had not undertaken any major bonus issue or a substantial authorised capital increase in the preceding 24 months. Separately, Reuters reported on March 26, 2026 that Aptus Pharma approved a bonus issue in the 3:2 ratio, after the board had recommended it on March 24.

Authorised capital hike: what changes on paper

Aptus Pharma’s board had proposed expanding the authorised share capital structure to create more headroom for future corporate actions. Based on the company’s disclosed structure, the number of shares under authorised capital is set to rise to 250.00 lakh shares from 71.50 lakh shares, with face value unchanged at ₹10 per share. In rupee terms, that translates to an authorised capital ceiling of ₹25.00 crore versus the earlier ₹7.15 crore. The company described this as a step to enhance financial flexibility for future initiatives. Importantly, an increase in authorised capital does not by itself issue new shares; it only raises the limit up to which the company can issue shares later, subject to necessary approvals.

Bonus issue: 3:2 and the funding source

For the bonus issue, the company has disclosed that it will capitalise ₹10.29 crore from the securities premium account. The total bonus shares proposed are 1,02,90,000 equity shares, which is 102.90 lakh shares. The entitlement remains straightforward: for every 2 existing shares, shareholders will receive 3 new shares. The company also disclosed a statutory auditor certification confirming adequate securities premium reserves of ₹10.68 crore as of March 24, 2026, supporting the proposed capitalisation. Aptus Pharma has asked investors to monitor its announcements for the record date and the credit date for the bonus shares.

How the paid-up capital and share count will change

The company has provided a pre and post snapshot of the paid-up capital impact of the bonus issue. Before the bonus, the number of shares stood at 68.60 lakh and paid-up capital at ₹6.86 crore. After the bonus issue, the number of shares is expected to rise to 171.50 lakh and paid-up capital to ₹17.15 crore, with the face value staying at ₹10 per share. This change is mechanical because bonus shares increase the equity base by converting reserves into share capital. While the share count increases, the company’s overall market value is not expected to change purely because of the bonus issuance, since the stock price typically adjusts to reflect the higher number of shares.

Key figures at a glance

Postal ballot process and timeline

The board meeting that cleared the proposals was held on March 24, 2026, and ran from 5:00 PM to 7:15 PM, according to the company’s disclosure. Aptus Pharma said it issued postal ballot notices along with explanatory statements, and appointed CDSL as the e-voting agency. The e-voting window opened on March 27, 2026 at 9:00 AM IST and closed on April 25, 2026 at 5:00 PM IST. The cut-off date for eligibility was March 24, 2026. The scrutiniser named for the process was Mr. Nalin T. Ganatra (FCS No. 3987). The company had indicated results would be declared on or before April 28, 2026.

Stock reaction and public reporting

A separate market report said Aptus Pharma shares were up about 2% at ₹349.30 after the bonus announcement, and hit an upper circuit on March 25. Reuters carried updates dated March 24 and March 26, 2026 around the board recommendation and subsequent approval of the bonus issue. One report also cited longer-period performance numbers, including a one-month rise of about 33%, a three-month gain of about 113%, and a six-month return of about 332%, alongside IPO reference prices of ₹70 (issue price) and ₹80.80 (listing price). These figures reflect secondary reporting included in the provided text and are not part of the company’s ballot outcome filing.

What investors should track next

Even after shareholder approval, the operational next steps matter for eligibility and timelines. The company has indicated that the record date for determining bonus entitlement will be announced in due course. Shareholders will want to watch for the official record date and the date when shares are credited to demat accounts. Aptus Pharma also flagged that investors should monitor announcements for the authorised share capital increase timeline. The postal ballot documentation has been made available on the company’s website and on the BSE platform.

Why the approvals matter

The authorised capital increase gives Aptus Pharma more flexibility to undertake future share issuances, corporate actions, or restructuring, without repeatedly returning to shareholders for a higher authorised ceiling, though further issuances would still require the relevant approvals. The bonus issue is a shareholder entitlement that increases the number of shares held without additional payment. It also raises the paid-up capital by converting part of reserves (securities premium) into equity. For investors, the immediate impact is typically a higher share count and an adjusted market price, while per-share metrics can change due to the expanded equity base, even though the company’s underlying business performance does not change simply because of a bonus.

Conclusion

Aptus Pharma’s postal ballot has delivered unanimous approval for both a 3:2 bonus issue and an increase in authorised share capital to ₹25.00 crore. The company has already disclosed the funding source for the bonus and the expected credit timeline of on or before May 23, 2026. The next key updates are the record date and the share credit date for the bonus allotment, along with formal implementation steps for the authorised capital hike. Investors will be watching company filings for these dates and any further disclosures tied to the expanded capital structure.